Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Burosumab (Crysvita)

decorative image of the issue cover

Published February 12, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses burosumab (Crysvita) injection, 10 mg/mL, 20 mg/mL, and 30 mg/mL, solution for injection, subcutaneous injection.
  • Indication: For the treatment of X-linked hypophosphatemia in adult and pediatric patients aged 6 months and older.